Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2006 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,859 | 0 | 11 | 449 | N/A |
| Receivables | 831 | N/A | N/A | N/A | N/A |
| TOTAL | $2,930 | $70 | $30 | $536 | $N/A |
| Non-Current Assets | |||||
| Investments And Advances | 0 | 32,005 | 70,766 | 69,029 | 0 |
| Other Non-Current Assets | 11 | 0 | 0 | 0 | 0 |
| TOTAL | $11 | $32,005 | $70,766 | $69,029 | $N/A |
| Total Assets | $2,941 | $32,075 | $70,796 | $69,566 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,153 | 622 | 551 | 86 | 0 |
| Accrued Expenses | 42,762 | N/A | N/A | 8 | N/A |
| TOTAL | $46,164 | $622 | $567 | $93 | $N/A |
| Non-Current Liabilities | |||||
| Long Term Debt | 548 | 1,952 | 690 | N/A | N/A |
| Other Non-Current Liabilities | 0 | 24,501 | 64,539 | 64,473 | 0 |
| TOTAL | $548 | $26,452 | $65,229 | $64,473 | $N/A |
| Total Liabilities | $46,712 | $27,075 | $65,796 | $64,566 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 269 | 272 | 904 | 904 | N/A |
| Common Shares | 43 | 3 | 3 | 3 | N/A |
| Retained earnings | -90,180 | 370 | -39 | -105 | N/A |
| TOTAL | $-43,771 | $5,000 | $5,000 | $5,000 | $N/A |
| Total Liabilities And Equity | $2,941 | $32,075 | $70,796 | $69,566 | $0 |